Glycated hemoglobin News and Research

RSS

The best meal timing for blood sugar may be earlier dinners

...

9 Jun 2026

NHS online diabetes program improves blood sugar and pressure

NHS England's Healthy Living program offers modest diabetes improvements; addressing engagement and access could enhance its public health effectiveness.

8 Jun 2026

How the right diet could support the gut bacteria that matter most

This review examines how gut keystone bacteria shape microbiome stability, disease risk, and responses to diet. It highlights why better identification methods, experimental validation, and precision diet-probiotic strategies are needed to restore gut homeostasis.

26 May 2026

Retatrutide reshapes metabolism in obesity and type 2 diabetes, study finds

Retatrutide altered circulating metabolites and lipids linked to fatty acid oxidation and insulin resistance in people with obesity, with or without type 2 diabetes. These biomarker changes suggest improved metabolic health, but the post-hoc analysis remains hypothesis-generating and does not prove direct clinical benefit.

26 May 2026

Indian adapted Mediterranean diet targets inflammation in heart disease trial

The paper describes a single-center randomized controlled trial testing whether an Indian Adapted Mediterranean Diet can reduce dietary inflammation in adults with stable coronary artery disease or moderate-to-high cardiovascular risk. The protocol will assess changes in the Dietary Inflammatory Index, inflammatory biomarkers, cardiometabolic risk factors, body measurements, and metabolic hormones over six months.

25 May 2026

CDC report reveals what 24 years of nutrition biomarkers say about America’s health

The 2026 CDC Nutrition Report will make nearly 24 years of NHANES biomarker data easier to use, covering up to 131 nutritional biomarkers in the US population aged 1 year and older. By standardizing blood and urine biomarker trends, demographic patterns, and comparisons of supplement use, the report aims to support nutrition policy, clinical reference intervals, and public health monitoring.

24 May 2026

Pregnancy-related disorders may shape offspring heart health into adulthood

Hypertensive disorders in pregnancy may lead to lasting cardiovascular issues in offspring, highlighting the need for improved maternal health strategies.

19 May 2026

New therapies could help type 1 diabetes care move beyond insulin alone

Disease-modifying therapies for type 1 diabetes are beginning to move care beyond insulin replacement by targeting immune dysregulation, beta-cell stress, and preservation of endogenous beta-cell function. Teplizumab marks a major clinical milestone, but the review emphasizes that durable metabolic remission will likely require earlier screening, better patient selection, and sequential or combination therapies.

18 May 2026

Once-daily orforglipron helps preserve weight loss after semaglutide or tirzepatide

Oral orforglipron helped adults maintain clinically meaningful weight loss after prior injectable tirzepatide or semaglutide therapy. The phase 3b ATTAIN-MAINTAIN trial suggests switching to once-daily oral therapy may help reduce weight regain when injectable treatment is discontinued.

13 May 2026

Could GLP-1 drugs help breast cancer patients live longer?

A large retrospective cohort study of adult female breast cancer patients found that GLP-1 receptor agonist use was associated with better all-cause survival and recurrence-free survival in patients with obesity or type 2 diabetes. The strongest associations were seen versus non-use in obesity and versus insulin or metformin in type 2 diabetes, while comparisons with SGLT2 inhibitors were less consistent and require further study.

12 May 2026

Two leading heart risk tools pass a major global test

A multinational Nature Medicine validation study found that PREVENT and SCORE2 cardiovascular risk equations performed generally well across 6.4 million people from observational cohorts and randomized trials. The findings support broader use of these tools for CVD risk stratification, while highlighting the need for local calibration and more validation in underrepresented regions.

11 May 2026

GLP-1 drugs promise wider health benefits, but experts urge caution on use

GLP-1 receptor agonists are reshaping care for type 2 diabetes, obesity, chronic kidney disease, and obstructive sleep apnea, with evidence for glycemic, weight-loss, cardiovascular, and renal benefits. The review urges nurse practitioners to balance expanding clinical promise with careful prescribing, patient education, monitoring, access advocacy, and vigilance for gastrointestinal, endocrine, pregnancy-related, and rare serious risks.

27 Apr 2026

Scientists will probe whether processing itself makes ultra-processed foods harmful

A randomized controlled trial protocol will test whether the cardiometabolic risks linked to ultra-processed foods stem from industrial processing, poor nutrient composition, or both. Using four controlled diets, researchers will separate the effects of UPF content from saturated fat, added sugar, and sodium on LDL cholesterol, insulin resistance, and blood pressure.

26 Apr 2026

Tirzepatide vs. semaglutide: Study compares cost and health outcomes in obesity

In a US societal-perspective lifetime simulation based on SURMOUNT-5 data, tirzepatide was projected to deliver lower total costs and better health outcomes than semaglutide for adults with obesity or overweight without type 2 diabetes.

22 Apr 2026

Why heart risk is hard to predict in type 1 diabetes

A European study reveals cardiovascular risk patterns in type 1 diabetes, highlighting the need for tailored prevention strategies to catch complications early.

20 Apr 2026

Irregular bedtimes double heart risk for those getting below 8 hours

Irregular sleep timing significantly impacts heart health, with inconsistent bedtimes linked to a higher risk of major cardiovascular events over a decade.

6 Apr 2026

Researchers show how smartwatches can help identify insulin resistance

Researchers developed a scalable framework that predicts insulin resistance using wearable-device signals, routine blood biomarkers, and demographic data, with stronger performance when these data streams were combined. The study also introduced an AI agent to explain insulin resistance risk, interpret results, and support earlier metabolic risk screening.

17 Mar 2026

Most weight lost on GLP-1 drugs returns within a year after stopping

The cessation of GLP-1RAs is linked to a 60% weight regain within a year, emphasizing the importance of tailored strategies for effective long-term weight loss.

9 Mar 2026

Weekend lie-ins may boost insulin sensitivity, but too much may backfire

This study explores the relationship between sleep patterns and insulin sensitivity, emphasizing the impact of weekday sleep and weekend catch-up on metabolism.

6 Mar 2026

How are GLP-1 drugs reshaping treatment for obesity, diabetes, and heart disease?

A comprehensive Lancet review synthesizes evidence from major clinical trials showing that GLP-1 receptor agonists and next-generation incretin therapies deliver substantial weight loss while reducing cardiovascular and kidney risks. Emerging dual, triple, and oral agents may further expand treatment options and improve outcomes across obesity, type 2 diabetes, and related metabolic diseases.

3 Mar 2026